TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-2.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.85B
AUM Growth
+$2.85B
(-8.4%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-2.54%
Top 10 Holdings %
Top 10 Hldgs %
35.96%
Holding
185
New
14
Increased
26
Reduced
25
Closed
10
Top Buys
| 1 |
AstraZeneca
AZN
|
$13.5M |
| 2 |
Stryker
SYK
|
$11.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$9.35M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$8.6M |
| 5 |
Becton Dickinson
BDX
|
$8.15M |
Top Sells
| 1 |
Moderna
MRNA
|
$37.6M |
| 2 |
Thermo Fisher Scientific
TMO
|
$32.3M |
| 3 |
Merck
MRK
|
$17.4M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$16.4M |
| 5 |
Danaher
DHR
|
$15.3M |
Sector Composition
| 1 | Healthcare | 95.64% |
| 2 | Real Estate | 3.21% |
| 3 | Industrials | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $168M | 5.91% | 330,026 +9,672 | +3% | +$4.93M |
|
2
Amgen
AMGN
$155B
| $139M | 4.88% | 574,918 | – | – |
|
3
Regeneron Pharmaceuticals
REGN
$61.5B
| $102M | 3.59% | 146,200 +3,151 | +2% | +$2.2M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $101M | 3.55% | 959,439 +61,899 | +7% | +$6.51M |
|
5
Gilead Sciences
GILD
$140B
| $100M | 3.52% | 1,686,565 | – | – |
|
6
Johnson & Johnson
JNJ
$427B
| $91.6M | 3.22% | 516,652 | – | – |
|
7
AbbVie
ABBV
$372B
| $88.9M | 3.12% | 548,144 +38,327 | +8% | +$6.21M |
|
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $80.6M | 2.83% | 308,884 +35,838 | +13% | +$9.35M |
|
9
Illumina
ILMN
$15.8B
| $79M | 2.78% | 226,212 | – | – |
|
10
Abbott
ABT
$231B
| $73.2M | 2.57% | 618,777 +35,500 | +6% | +$4.2M |
|
|
11
AstraZeneca
AZN
$248B
| $65.7M | 2.31% | 990,675 +203,190 | +26% | +$13.5M |
|
12
McKesson
MCK
$85.4B
| $63.1M | 2.22% | 206,022 +17,500 | +9% | +$5.36M |
|
13
Pfizer
PFE
$141B
| $60.7M | 2.13% | 1,171,903 | – | – |
|
14
Eli Lilly
LLY
$657B
| $60.7M | 2.13% | 211,832 -18,600 | -8% | -$5.33M |
|
|
15
Stryker
SYK
$150B
| $60.3M | 2.12% | 225,678 +42,096 | +23% | +$11.3M |
|
|
16
Thermo Fisher Scientific
TMO
$186B
| $57.7M | 2.02% | 97,605 -54,721 | -36% | -$32.3M |
|
|
17
Moderna
MRNA
$9.37B
| $56.6M | 1.99% | 328,524 -218,100 | -40% | -$37.6M |
|
18
Bristol-Myers Squibb
BMY
$96B
| $52.9M | 1.86% | 723,876 -23,167 | -3% | -$1.69M |
|
19
Medtronic
MDT
$119B
| $48.3M | 1.7% | 435,140 -70,720 | -14% | -$7.85M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $47.6M | 1.67% | 330,561 -68,966 | -17% | -$9.93M |
|
|
21
Merck
MRK
$210B
| $47.2M | 1.66% | 575,622 -212,500 | -27% | -$17.4M |
|
|
22
Danaher
DHR
$147B
| $44M | 1.55% | 150,145 -52,215 | -26% | -$15.3M |
|
23
Cigna
CI
$80.3B
| $41.2M | 1.45% | 172,023 +28,600 | +20% | +$6.85M |
|
24
Idexx Laboratories
IDXX
$51.8B
| $33.5M | 1.18% | 61,217 -18,446 | -23% | -$10.1M |
|
25
Molina Healthcare
MOH
$9.8B
| $31.5M | 1.11% | 94,525 -3,800 | -4% | -$1.27M |
|